Meletios Athanasios Dimopoulos
Impact in
- Hematology top 0.01%
- Multiple Myeloma Research and Treatments
- Oncology top 0.01%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Bone health and treatments
Papers in
- Hematology 1.0k
- Multiple Myeloma Research and Treatments 967
- Oncology 687
- Peptidase Inhibition and Analysis 224
- Cancer Treatment and Pharmacology 223
- Bone health and treatments 87
- Co-authors
- Evangelos Terpos (251 shared papers)Efstathios Kastritis (251 shared papers)Lia Angela Moulopoulos (71 shared papers)Raymond Alexanian (44 shared papers)Maria Gavriatopoulou (251 shared papers)Ioannis Ntanasis‐Stathopoulos (186 shared papers)Jesús F. San Miguel (82 shared papers)Dimitra Gika (83 shared papers)
- Journals
- Blood (324 papers)Annals of Oncology (66 papers)Journal of Clinical Oncology (63 papers)Leukemia (61 papers)American Journal of Hematology (59 papers)
- Partner nations
- GreeceUnited StatesFrance
In The Last Decade
Meletios Athanasios Dimopoulos
1.8k papers receiving 97.6k citations
Meletios Athanasios Dimopoulos's Hit Papers
Peers
Comparison fields: 5 of 196
- Hematology 58.8k
- Oncology 37.1k
- Genetics 14.5k
- Molecular Biology 41.2k
- Pathology and Forensic Medicine 9.0k
Countries citing papers authored by Meletios Athanasios Dimopoulos
This map shows the geographic impact of Meletios Athanasios Dimopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meletios Athanasios Dimopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meletios Athanasios Dimopoulos more than expected).
Fields of papers citing papers by Meletios Athanasios Dimopoulos
This network shows the impact of papers produced by Meletios Athanasios Dimopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meletios Athanasios Dimopoulos. The network helps show where Meletios Athanasios Dimopoulos may publish in the future.
Co-authors
The 25 scholars most cited alongside Meletios Athanasios Dimopoulos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.9k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Hit paper breakdown → | 2014 | 3585 |
| 2 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Hit paper breakdown → | 2016 | 2367 |
| 3 | International uniform response criteria for multiple myeloma Hit paper breakdown → | 2006 | 2288 |
| 4 | Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group Hit paper breakdown → | 2015 | 1664 |
| 5 | Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma Hit paper breakdown → | 2008 | 1579 |
| 6 | Hematological findings and complications of COVID ‐19 Hit paper breakdown → | 2020 | 1263 |
| 7 | Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma Hit paper breakdown → | 2007 | 1228 |
| 8 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2016 | 1200 |
| 9 | Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Hit paper breakdown → | 2014 | 1125 |
| 10 | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma Hit paper breakdown → | 2015 | 1112 |
| 11 | Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors Hit paper breakdown → | 2005 | 939 |
| 12 | Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 Hit paper breakdown → | 2011 | 914 |
| 13 | Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma Hit paper breakdown → | 1996 | 881 |
| 14 | Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma Hit paper breakdown → | 2017 | 798 |
| 15 | New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes Hit paper breakdown → | 2012 | 777 |
| 16 | Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia Hit paper breakdown → | 2003 | 755 |
| 17 | Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study Hit paper breakdown → | 2015 | 736 |
| 18 | Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Hit paper breakdown → | 2014 | 696 |
| 19 | Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2013 | 690 |
| 20 | Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma Hit paper breakdown → | 2014 | 686 |
About Meletios Athanasios Dimopoulos
Meletios Athanasios Dimopoulos is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Pathology and Forensic Medicine, having authored 1.9k papers that have together received 100.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (967 papers), Protein Degradation and Inhibitors (328 papers), Peptidase Inhibition and Analysis (224 papers), Cancer Treatment and Pharmacology (223 papers), Chronic Lymphocytic Leukemia Research (220 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (164 papers), Lymphoma Diagnosis and Treatment (147 papers) and Bone health and treatments (87 papers). The work is most often cited by research in Hematology (58.8k citations), Oncology (37.1k citations), Genetics (14.5k citations), Molecular Biology (41.2k citations) and Pathology and Forensic Medicine (9.0k citations). Meletios Athanasios Dimopoulos has collaborated with scholars based in Greece, United States and France. Frequent co-authors include Evangelos Terpos, Efstathios Kastritis, Lia Angela Moulopoulos, Raymond Alexanian, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Jesús F. San Miguel, Dimitra Gika, Christos Papadimitriou and Theodora Psaltopoulou. Their work appears in journals such as Blood, Annals of Oncology, Journal of Clinical Oncology, Leukemia and American Journal of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.